Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
Matteo Tonnini, Margarita Papatheodoridi, Sophie Metivier, Nathalie Ganne, Louis D'Alteroche, Isabelle Rosa, Dominique Roulot, Anne Gervais, Mauro Viganò, Alessandra Mangia, Maurizia R Brunetto, Nasser Semmo, Alessia Ciancio, Stanislas Pol, Teresa A Santantonio, Gabriella Verucchi, Eric Billaud, Kosh Agarwal, Xavier Causse, Nicola Coppola, Massimo Puoti, Elisabetta Degasperi, Soo Aleman, Christoph Schramm, Pietro Lampertico, Alessandro Federico, Fabien Zoulim, Victor De Ledinghen, Anne Minello, Marie-Noelle Hilleret, Thomas Reiberger, Mathias Jachs, Heiner Wedemeyer, Hartmut Schmidt, Uta Merle, George Papatheodoridis, Frank Tacke, Christopher Dietz-Fricke, Maria Paola Anolli, Gianpiero D'Offizi, Francesco di Maria, Caroline Zöllner, Ivana Carey, Florian Van Bömmel, Mariana Cardoso, Adriano Pellicelli, Bruno Roche, Jérome Dumortier, Frederic Heluwaert, Isabelle Ollivier, Alessandro Loglio, Francesca Pileri, Monia Maracci, Jean-Pierre Arpurt, Karl Barange
Journal of hepatology 2025;82(6):1012-1022